ASX · ICR.AX
Intelicare Holdings Limited
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
Loading market information…
ASX · HIQ.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:39 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
HITIQ Limited’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow HITIQ Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HITIQ Limited is an Australian enterprise focused on developing and commercializing advanced technology for concussion management. Its Nexus software platform delivers comprehensive data and analytical insights concerning head impacts, empowering informed decision-making to enhance care for athletes. The company also offers CoVR, a virtual reality-based system for assessing cognitive and oculomotor functions, capable of identifying impairments in areas such as hand-eye coordination, memory, and critical thinking. Additionally, CSX provides a straightforward sideline tool for concussion evaluation, generating digital records that can be easily shared with medical professionals, family members, and organizations to ensure coordinated athlete support. Established in 2015, the company maintains its headquarters in Melbourne, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.01-A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
A$0.08-A$0.00 (-5.06%)
Vectus Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 83.52% below the high.
A$0.04-A$0.00 (-5.41%)
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
A$0.01-A$0.00 (0.0%)
Cann Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
A$0.08A$0.00 (0.0%)
TALi Digital Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.00+A$0.00 (0.0%)
Percheron Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
